Team Grant : Canadian Research Initiative on Substance Misuse (CRISM) Phase II: Regional Nodes

Recognizing a need for independent research on substance use, CIHR is launching Phase II of the Canadian Research Initiative in Substance Misuse (CRISM). CRISM is currently comprised of four large multi-disciplinary, integrated teams (“Nodes”) of substance use researchers, service providers, decision makers and people with lived and living experience, collectively known as the “Network”. 
CRISM Phase II looks to build and expand on the successes during the Initiative’s first phase by:
- increasing the number of Regional Nodes to enhance geographic coverage while maintaining the “Network of Networks” and expanding capacity
- creating a dedicated coordinating and governance structure to strengthen the governance, coordination and communication functions of the Network
- expanding the reach and impact of Indigenous (i.e., First Nations, Inuit, Métis, and Urban Indigenous communities) engagement in all aspects of the Network through an Indigenous-led platform
- developing an integrated training platform to build research capacity
- applying the Network’s clinical trial expertise for a new national controlled trial in the management of methamphetamine use disorder aligned with the NIDA CTN   
- enhancing knowledge translation (KT) capacity to successfully meet the evidence needs of policy and decision makers at the federal, provincial/territorial level and other jurisdictions, as well as increasing engagement with individuals with lived and living experiences

Eligibility 

For a Regional Node LOI to be eligible:

  1. The Nominated Principal Applicant must be an independent researcher.
  2. The Nominated Principal Applicant must be appointed at an eligible institution within the geographic area covered by the Regional Node they are leading by the effective date of funding.
  3. The research team must include at least one Principal Applicant who self-identifies as Indigenous (First Nations, Inuit or Métis) and/or demonstrates a track record of meaningful and culturally safe involvement with Indigenous Peoples. At the Full Application stage, a one-page document describing how they meet this requirement must be submitted as an “Other” attachment.
  4. At least one project participant must be identified as responsible for directing the Methamphetamine Use Disorder Controlled Trial within that Regional Node.
  5. At least one project participant, other than the Nominated Principal Applicant, must be a Service Provider for problematic substance use, under the broad definition of a Knowledge User.
  6. At least one project participant, other than the Nominated Principal Applicant and the Service Provider, must be a Representative from one of these categories: people with lived and living experience, including caregivers, family members, advocacy groups.
  7. The research team must include a Sex and Gender Champion listed as Nominated Principal Applicant, Principal Applicant or Co-Applicant. Champions are researchers able to meaningfully integrate considerations of sex and gender throughout all aspects of the project design, methods, analysis, implementation and reporting. The Sex and Gender Champion must have successfully completed one of the sex- and gender-based analysis training modules available online through the CIHR Institute of Gender and Health and submit a Certificate of Completion. Please select and complete the training module most applicable to your research project. See Additional Information for further important information on the Champion role.

In addition to meeting the requirements for the LOI, for a Regional Node Full Application to be eligible:

  1. The Full Application must have the support of regional or provincial health authorities and/or Ministries of Health, and (optional) local health units. A minimum of two (2) letters of support are required (with at least one coming from regional or provincial health authorities or Ministries of Health), but no more than five (5) letters of support in total. 

Funds Available

The maximum amount per grant is $400,000 per year for up to six (6) years, for a total of $2,400,000 per grant.

How to Apply

The application process for this funding opportunity is comprised of two stages:

1) Regional Node Letter of Intent

2a) Regional Node Full Application and 2b) Controlled Trial Application

WEBSITE

Deadlines

Regional Node LOI: June 15, 2021

Regional Node Full Application and Controlled Trial Application: January 6, 2022

SFU Signature Sheet, Routing Slip and all supporting documentation are due to ORS 3 business days before the application deadline

SFU acknowledges the principles of Ownership, Control, Access and Possession (OCAP®) see: https://fnigc.ca/ocap-training/) with regard to how First Nations data is collected, protected or shared.

Upcoming Deadlines

External
Internal
January 06, 2022January 06, 2022 Verified Date
January 03, 2022 Jan. 03, 2022 January 03, 2022 16:00:00 January 03, 2022 16:00:00 America/Vancouver Application Deadline: Team Grant : Canadian Research Initiative on Substance Misuse (CRISM) Phase II: Regional Nodes Recognizing a need for independent research on substance use, CIHR is launching Phase II of the Canadian Research Initiative in Substance Misuse (CRISM). CRISM is currently comprised of four large multi-disciplinary, integrated teams (“Nodes”) of substance use researchers, service providers, decision makers and people with lived and living experience, collectively known as the “Network”. CRISM Phase II looks to build and expand on the successes during the Initiative’s first phase by: - increasing the number of Regional Nodes to enhance geographic coverage while maintaining the “Network of Networks” and expanding capacity - creating a dedicated coordinating and governance structure to strengthen the governance, coordination and communication functions of the Network - expanding the reach and impact of Indigenous (i.e., First Nations, Inuit, Métis, and Urban Indigenous communities) engagement in all aspects of the Network through an Indigenous-led platform - developing an integrated training platform to build research capacity - applying the Network’s clinical trial expertise for a new national controlled trial in the management of methamphetamine use disorder aligned with the NIDA CTN - enhancing knowledge translation (KT) capacity to successfully meet the evidence needs of policy and decision makers at the federal, provincial/territorial level and other jurisdictions, as well as increasing engagement with individuals with lived and living experiences .

x